Multispecific antibody and use thereof
By designing multispecific antibodies targeting GPRC5D and/or BCMA and CD3, the problem of insufficient tumor-killing efficacy in the heterogeneous environment of tumors in existing technologies has been solved, achieving higher tumor killing rate and reducing recurrence, and is suitable for the treatment of multiple myeloma.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- VELAVIGO (SHANGHAI) LTD
- Filing Date
- 2026-01-12
- Publication Date
- 2026-07-16
AI Technical Summary
Existing multispecific antibodies targeting T cells have insufficient tumor-killing efficacy in the heterogeneous environment of tumors and have toxic side effects related to T cell activation, making them difficult to effectively treat relapsed and drug-resistant multiple myeloma.
Bispecific and trispecific antibodies targeting GPRC5D and/or BCMA and CD3 were designed. Through immune screening, unique anti-CD3 functional sequences and anti-GPRC5D and BCMA immunoglobulin single variable domains were obtained, achieving a suitable combination of multiple targets and regulating the role of T cell adaptor antibodies in related cell activation, tumor killing and cytokine release.
It improved the tumor killing rate, reduced residual tumor foci, reduced the recurrence rate of cancer patients, enhanced clinical efficacy, and showed good druggability.
Smart Images
Figure PCTCN2026071941-FTAPPB-I100001 
Figure PCTCN2026071941-FTAPPB-I100002 
Figure PCTCN2026071941-FTAPPB-I100003